COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection)
Conditions
Interventions
Current intervention as of 13/05/2024:
Individuals diagnosed with SARS-CoV-2 infection (index cases) and their close contacts identified via the contact tracing activities of the Department of Health
i.e., as early as possible after identification as an index case), as well as after 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months after identification as an index case. Participants wil
Sponsors
University of Zurich
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current participant inclusion criteria as of 08/07/2022: Index cases: 1. Individuals newly diagnosed with SARS-CoV-2 infection in the Canton of Zurich from the start of the study (prospective index cases) 2. Individuals previously diagnosed with SARS-CoV-2 infection in the Canton of Zurich between February 2020 and the start of the study (retrospective index cases) Close contacts: 1. Symptomatic and asymptomatic close contacts of prospective index cases as identified by routine contact tracing by the Department of Health of the Canton of Zurich _____ Previous participant inclusion criteria: Index cases: 1. Individuals newly diagnosed with SARS-CoV-2 infection in the Canton of Zurich from the start of the study (prospective index cases) 2. Individuals previously diagnosed with SARS-CoV-2 infection in the Canton of Zurich between February 2020 and the start of the study (retrospective index cases) Close contacts: 1. Symptomatic and asymptomatic close contacts of prospective index cases as identified by routine contact tracing by the Health Directorate of the Canton of Zurich
Exclusion criteria
Exclusion criteria: 1. Children and adolescents aged <18 years 2. Insufficient knowledge of the German language 3. Individuals with primary residence outside of the Canton of Zurich, Switzerland 4. Individuals that are unable to follow study procedures 5. Individuals that cannot be reached on maximum of 5 attempts 6. Individuals that do not provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measures as of 08/07/2022: WP1. Proportion of SARS-CoV-2 infected individuals developing long-term symptoms or complications related to COVID-19, measured through participant questionnaires and clinical file review up to 36 months WP2. Secondary infection rate and secondary clinical attack rate among close contacts of SARS-CoV-2 infected index cases, measured through participant questionnaires and SARS-CoV-2 PCR testing at enrollment and at the end of quarantine WP3. Transmission networks constructed via routine contact tracing data. WP4.1. Proportion of SARS-CoV-2 infected individuals with measurable anti-SARS-CoV-2 IgA and IgG antibodies, measured using Luminex technology-based antibody testing at 2 weeks, 1 month, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months after laboratory confirmation of SARS-CoV-2 infection WP4.2. Proportion of SARS-CoV-2 infected individuals with SARS-CoV-2 antigen-specific T cells, measured using IFN-gamma assays at 2 weeks, 1 month, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months after laboratory confirmation of SARS-CoV-2 infection _____ Previous primary outcome measures: WP1. Proportion of SARS-CoV-2 infected individuals developing long-term complications related to COVID-19, measured through participant questionnaires and clinical file review at 12 months WP2. Secondary infection rate and secondary clinical attack rate among close contacts of SARS-CoV-2 infected index cases, measured through participant questionnaires and SARS-CoV-2 PCR testing at enrollment and at the end of quarantine WP3. Transmission network constructed via routine contact tracing data and via phylogenetic analyses of SARS-CoV-2 sequences as determined at the end of follow-up WP4.1. Proportion of SARS-CoV-2 infected individuals with measurable anti-SARS-CoV-2 IgM, IgA and IgG antibodies, measured using ABCORA testing at 2 weeks, 1 month, 3 months, 6 months and 12 months after labo | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 08/07/2022: WP1.1. General and COVID-19 specific health-related quality of life, measured using the EQ-5D, DASS-21, Fatigue Assessment Scale and MRC dyspnea scale at 2 weeks, 1 month, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months after laboratory confirmation of SARS-CoV-2 infection WP1.2. Proportion of individuals with severe disease courses, defined as requiring hospitalization or leading to death within 28 days of confirmation of SARS-CoV-2 infection, measured through participant questionnaires and clinical file review WP1.3. Proportion of individuals diagnosed with SARS-CoV-2 reinfection within 36 months of confirmation of SARS-CoV-2 infection, measured using participant questionnaires and contact tracing data WP1.4. Proportion of individuals diagnosed with a new infection or reactivation of a chronic infection by any pathogen within 36 months of laboratory confirmation of SARS-CoV-2 infection, measured through participant questionnaires and clinical file review WP1.5. Proportion of individuals requiring hospitalization, ICU admission, mechanical ventilation or death (all cause and COVID-19 related) within 36 months after confirmation of SARS-CoV-2 infection, measured through participant questionnaires and clinical file review WP1.6. Proportion of individuals with self-reported symptoms and/or known risk factors at time of SARS-CoV-2 testing, measured using participant questionnaires WP1.7. Proportion of individuals that received treatment against SARS-CoV-2, measured through participant questionnaires and clinical file review at enrollment WP2.1. Proportion of symptomatic and asymptomatic SARS-CoV-2 infected individuals among close contacts of index cases, measured using participant questionnaires and contact tracing data at enrollment and at the end of quarantine WP2.2. Serial interval of SARS-CoV-2 infection, calculated based on data from participant questionnaires WP2.3. Factors potentia | — |
Countries
Switzerland
Contacts
Public ContactDominik Menges
Outcome results
None listed